Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to -$143.7 million.

  • Ligand Pharmaceuticals' Cash from Investing Activities fell 659.98% to -$353.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$397.8 million, marking a year-over-year decrease of 244.97%. This contributed to the annual value of -$143.7 million for FY2024, which is 1129.79% down from last year.
  • As of FY2024, Ligand Pharmaceuticals' Cash from Investing Activities stood at -$143.7 million, which was down 1,129.79% from -$11.7 million recorded in FY2023.
  • In the past 5 years, Ligand Pharmaceuticals' Cash from Investing Activities registered a high of $231.6 million during FY2020, and its lowest value of -$143.7 million during FY2024.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$11.7 million (2023), whereas its average is $2.8 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first spiked by 436.07% in 2022, then plummeted by 1,129.79% in 2024.
  • Ligand Pharmaceuticals' Cash from Investing Activities (Yearly) stood at $231.6 million in 2020, then slumped by 86.82% to $30.5 million in 2021, then soared by 436.07% to $163.6 million in 2022, then tumbled by 107.14% to -$11.7 million in 2023, then plummeted by 1,129.79% to -$143.7 million in 2024.